IDEAS home Printed from https://ideas.repec.org/a/epw/pharma/v2y2022i1id715.html

Evaluation of the Anti-ulcer Effect of Extra Virgin Avocado (Persea americana) Oil in Rats

Author

Listed:
  • Samuel Offor

    (University of Uyo, Nigeria)

  • Adedayo Adedoyin Tologbonse

    (University of Uyo, Nigeria)

  • Sifon Obong John Akpan

    (University of Uyo, Nigeria)

  • Victor Udo Anah

    (University of Uyo, Nigeria)

  • Enobong Anietie Edward

    (University of Uyo, Nigeria)

Abstract

Peptic ulcer disease is a gastrointestinal disorder of high mortality and morbidity. Therapy of this disease condition with conventional drugs presents therapeutic challenge due to incidents of unwanted side effects, and the high cost of these medications. The use of products from natural sources will provide useful alternatives due to their minimal side effects, being inexpensive, and readily available, especially in resource-challenged nations of the continent of Africa and other developing economies. Oils derived from plants are increasingly being used in management of several disease conditions. This study aims at evaluating the antiulcer activity of extra virgin avocado oil in rodents using ethanol-induced, and indomethacin-induced ulcer models. Test group was given extra virgin avocado oil (1ml per 250g weight) for 7 days before induction of ulcer. Positive controls received omeprazole 30 mg/kg, while negative control animals were given distilled water (10ml/kg) for 7 days respectively, before induction of ulcer. The stomachs were excised and their histopathological examinations carried out. Avocado oil significantly reduced the ulcer index in both models when compared to the negative control group, and histopathological findings corroborate that the oil ameliorates ulcerations in both models. The present study has demonstrated that extra virgin avocado oil possesses significant antiulcer activity.

Suggested Citation

Handle: RePEc:epw:pharma:v:2:y:2022:i:1:id:715
DOI: 10.24018/ejpharma.2022.2.1.15
as

Download full text from publisher

File URL: https://eu-opensci.org/index.php/pharma/article/view/715
File Function: Abstract page
Download Restriction: no

File URL: https://eu-opensci.org/index.php/pharma/article/download/715/301
File Function: Full text
Download Restriction: no

File URL: https://libkey.io/10.24018/ejpharma.2022.2.1.15?utm_source=ideas
LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
---><---

More about this item

Keywords

;
;
;
;

Statistics

Access and download statistics

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:pharma:v:2:y:2022:i:1:id:715. See general information about how to correct material in RePEc.

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

We have no bibliographic references for this item. You can help adding them by using this form .

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/pharma .

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.